Combination of Bortezomib and Mitotic Inhibitors Down-Modulate Bcr-Abl and Efficiently Eliminates Tyrosine-Kinase Inhibitor Sensitive and Resistant Bcr-Abl-Positive Leukemic Cells
Octavian Bucur(Beth Israel Deaconess Medical Center), Roya Khosravi‐Far(Harvard University)
Cited by 24
Related Papers
A Double Hit to Kill Tumor and Endothelial Cells by TRAIL and Antiangiogenic 3TSR
|Cancer Research|2009|52
Proteasome Inhibition Causes Regression of Leukemia and Abrogates BCR-ABL–Induced Evasion of Apoptosis in Part through Regulation of Forkhead Tumor Suppressors
|Cancer Research|2009|48
A novel caspase 8 selective small molecule potentiates TRAIL-induced cell death
|Scientific Reports|2015|28
PLK1 is a binding partner and a negative regulator of FOXO3 tumor suppressor
|Discoveries|2014|26
killerFLIP: a novel lytic peptide specifically inducing cancer cell death
|Cell Death and Disease|2013|17